Announcements Trials
Browse Landscape

Status

Unknown 2Terminated 2Withdrawn 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Non-Small Cell Lung Cancer ALK-positive 1Non Small Cell Lung Cancer Metastatic 1Meningeal Carcinomatosis 1Lung Neoplasms 1Brain Neoplasms 1Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer 1

Interventions

pembrolizumab 29Carboplatin 27Specimen Handling 21durvalumab 20Pemetrexed 18Cisplatin 17Paclitaxel 16atezolizumab 15Nivolumab 15Magnetic Resonance Spectroscopy 15osimertinib 11Radiosurgery 11Radiotherapy 10Immunoglobulin G 10Etoposide 10Docetaxel 10Disulfides 10Radiation 9Taxes 8Gemcitabine 8Biopsy 8Blood Specimen Collection 7Standard of Care 6Practice Guidelines as Topic 6Ipilimumab 6Surveys and Questionnaires 5Platinum 5Bronchoscopy 5Bevacizumab 5Ramucirumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Lung Neoplasms × lorlatinib × Clear all
NCT07567352 2026-05-12

A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment

Pfizer

Active not recruiting
200 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡